<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intellectual disability in children: Evaluation for a cause</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intellectual disability in children: Evaluation for a cause</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intellectual disability in children: Evaluation for a cause</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Penelope Pivalizza, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seema R Lalani, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intellectual disability (ID) is a neurodevelopmental disorder with multiple etiologies. It is characterized by deficits in intellectual and adaptive functioning of varying severity, presenting before 18 years of age. ID encompasses a broad spectrum of functioning, disability, and strengths [<a href="#rid1">1</a>]. ID affects approximately 1 percent of the population. It is an important public health issue because of its prevalence and the need for support services. Its management requires early diagnosis and intervention, including access to health care and appropriate supports. Identifying a cause enables condition-specific intervention, surveillance, and appropriate counseling, with anticipation of possible medical or behavioral comorbidities [<a href="#rid2">2</a>].</p><p>This topic reviews the epidemiology of ID and the evaluation of affected children for a specific cause. Other aspects of ID are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6191.html" rel="external">"Intellectual disability (ID) in children: Management, outcomes, and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H1875180106"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The following terms are used throughout this topic (see  <a class="medical medical_review" href="/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis", section on 'Terminology'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intellectual disability</strong> – Intellectual disability (ID) is a neurodevelopmental disorder characterized by deficits in intellectual and adaptive skills, affecting at least one of three adaptive domains (conceptual, social, and practical) with varying severity  (<a class="graphic graphic_table graphicRef90174 graphicRef95384" href="/d/graphic/90174.html" rel="external">table 1A-B</a>). The older term "mental retardation" is no longer used in clinical practice. The severity of ID is defined according to the level of adaptive impairment and the level of support needed to address impaired adaptive functioning. Standardized intelligence quotient testing is no longer used to classify ID severity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Global developmental delay</strong> – Global developmental delay (GDD) is the preferred term to describe intellectual and adaptive impairment in infants and children &lt;5 years old who fail to meet expected developmental milestones in multiple areas of functioning. Not all children with GDD meet criteria for ID as they grow older. The term ID is usually applied to children at approximately 5 years of age, but may be applied to children &lt;5 years old who meet ID criteria.</p><p></p><p class="headingAnchor" id="H167153175"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H167153413"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The prevalence of ID varies substantially among studies due to differences in study design, diagnostic approach, severity of the condition, and population characteristics, such as age. In the general population, the prevalence of ID (with deficits in both adaptive and intellectual functioning) is approximately 1 percent [<a href="#rid3">3-8</a>]. ID is mild in approximately 85 percent of affected individuals.</p><p>The prevalence of global developmental delay (GDD) is estimated to be 1 to 3 percent [<a href="#rid9">9</a>]. GDD does not necessarily predict later ID, although there is a strong correlation.</p><p>The prevalence of ID varies with age and gender. It is highest in school-age and male individuals. Approximately 20 to 30 percent more males are diagnosed with ID compared with females [<a href="#rid10">10</a>]; however, the gender difference diminishes with more severe ID. The prevalence of mild ID is more variable across populations than severe ID, varying with environmental factors of maternal education, educational access, or opportunities and access to health care [<a href="#rid11">11,12</a>].</p><p class="headingAnchor" id="H167153419"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Important risk factors for ID include low level of maternal education, advanced maternal age, and poverty [<a href="#rid13">13-15</a>]. Many other risk factors for ID have been identified and they differ somewhat according to the severity of ID.</p><p>In a large birth cohort in Tennessee, low level of maternal education was the strongest predictor of mild ID, and a stronger predictor than maternal age [<a href="#rid14">14</a>]. The risk of ID in children of mothers with ≤12 years of education was seven times greater compared with mothers with some post-secondary education, and three times greater than those with a high school diploma. The risk for mild ID was slightly increased in children born to mothers 15 to 19 years old, while the risk of moderate to severe ID was greatest in those born to mothers 40 to 44 years of age.</p><p>In a study of children born in California between 1987 and 1994, the risk of unexplained ID was increased among males, low birth weight infants, multiple births, second or later-born children, older maternal age at delivery, and lower maternal level of education [<a href="#rid13">13</a>].</p><p>The risk for ID also appears to be associated with advanced paternal age; one study found that paternal age &gt;40 years is associated with an increased risk for mild to moderate ID [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H167148873"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>The causes of ID are extensive and include conditions that interfere with brain development and functioning. Among the known causes of ID, the majority are genetic abnormalities [<a href="#rid17">17-19</a>].</p><p>Metabolic disorders can cause ID or may be comorbid. ID can present alone or with neurologic abnormalities such as epilepsy or structural brain defects, or with other congenital anomalies.</p><p>A minority of cases have environmental causes such as teratogens, toxins, infections, trauma, birth asphyxia, and nutritional deficiencies. The timing, dose, and extent of environmental exposure are important [<a href="#rid20">20</a>]. ID causation may be prenatal, perinatal, or postnatal.</p><p class="headingAnchor" id="H167148879"><span class="h2">Genetic causes</span><span class="headingEndMark"> — </span>Genetic conditions are increasingly being diagnosed by technologic advances in genetic testing; a specific genetic cause can be identified in &gt;50 percent of individuals with ID referred for evaluation [<a href="#rid17">17,18,21</a>]. The increasing use of next-generation DNA sequencing techniques (eg, whole exome sequencing [WES]) has uncovered many more genes involved in both syndromic and nonsyndromic forms of ID [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a>.)</p><p>Chromosomal microarray analysis (CMA) is recommended as first-line test for most patients with ID, unless the patient has features suggesting a specific disorder [<a href="#rid11">11,23</a>]. (See <a class="local">'Chromosomal microarray analysis'</a> below and <a class="local">'Testing for specific disorders'</a> below.)</p><p>Metabolic disorders are often associated with ID and may be causative in up to 3 percent of patients with unexplained ID [<a href="#rid24">24</a>]. Newborn screening advances have been pivotal in the early diagnosis and treatment of affected children. Increasing identification of treatable inborn errors of metabolism (IEM) has enabled specific intervention, functional improvement, or stabilization. Although children with metabolic disorders may present with ID alone, most have additional features (eg, episodic decompensation, undernutrition, seizures, developmental regression, abnormal findings on neurologic examination, and/or hepatomegaly) [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder", section on 'Newborn screening'</a>.)</p><p>A genetic abnormality may present as ID alone (nonsyndromic ID), or as ID associated with a syndrome (syndromic ID) [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis", section on 'Syndromic versus nonsyndromic intellectual disability'</a>.)</p><p>Detailed information about many genetic syndromes is available by searching for the disorder in the following open-access databases:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fomim&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F1mEzbrra1EyPWuMKBWRSz2FZxizAt9vS6osbKh7UCRu&amp;TOPIC_ID=6189" target="_blank">Online Mendelian Inheritance in Man (OMIM)</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1116%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzEAfmGCQvouTQ5LbX9C3XVSHxjYdvs2mgciTuJx4IXLQ%3D%3D&amp;TOPIC_ID=6189" target="_blank">GeneReviews</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=ODIqmPyH03K5IrNHL4oottyJV%2BtPhS7Gs3UPQx%2BHe7Xh4E9j4nqEtGCcPjsW%2BwBz&amp;TOPIC_ID=6189" target="_blank">Genetic Testing Registry</a></p><p></p><p>Some important genetic causes of ID include the following:</p><p class="headingAnchor" id="H167148885"><span class="h3">Chromosomal abnormalities</span><span class="headingEndMark"> — </span>Chromosomal aberrations as a group are the most common known cause of ID [<a href="#rid11">11</a>]. Among the genetic causes, cytogenetic abnormalities visible under a light microscope (ie, detectable by G-banded chromosome analysis) account for approximately 15 percent of cases [<a href="#rid27">27</a>]. Nearly all unbalanced chromosomal rearrangements that are cytogenetically visible can cause ID (with the exception of sex chromosome abnormalities). (See <a class="local">'Testing for specific disorders'</a> below and  <a class="medical medical_review" href="/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Chromosomal analysis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Down syndrome</strong> – Down syndrome, or trisomy 21, is the single most common known genetic cause of ID [<a href="#rid11">11,28</a>]. (See  <a class="medical medical_review" href="/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deletion, microdeletion, and duplication syndromes</strong> – Genomic disorders resulting from deletions, microdeletions, or duplications of chromosomal material have been recognized as a frequent cause of ID. Many of these chromosomal abnormalities are below the resolution threshold of G-banded chromosome analysis and therefore CMA or fluorescence in situ hybridization (FISH) are required for detection.</p><p></p><p class="bulletIndent1">Examples of some more common microdeletion syndromes associated with ID include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>22q11 deletion syndrome (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F188400&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2FC0SpiWvUL7CRFS0vX9qLUbmH2m%2Fe%2FxB%2BNqsffxqge5&amp;TOPIC_ID=6189" target="_blank">DiGeorge syndrome</a>, also known as Velocardiofacial syndrome) (see  <a class="medical medical_review" href="/d/html/83396.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>7q11.23 deletion syndrome (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F194050&amp;token=G%2BkOOgscg7PQzd0gXq5S9w%2FfgLne1x2BeDokIX%2BVZds6ivKxZmphqDj8Eyof8aL6&amp;TOPIC_ID=6189" target="_blank">Williams syndrome</a>) [<a href="#rid29">29</a>] (see  <a class="medical medical_review" href="/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)", section on '7q11.23 deletion syndrome (Williams syndrome)'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>17p11.2 deletion syndrome (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F182290&amp;token=G%2BkOOgscg7PQzd0gXq5S96RLtGeIiCFlvgYUXm%2FJcazKWy1Aw4R2D0wqYjWjUFGw&amp;TOPIC_ID=6189" target="_blank">Smith-Magenis syndrome</a>) [<a href="#rid30">30</a>] (see  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '17p11.2 deletion syndrome (Smith-Magenis syndrome)'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>15q11-13 maternal and paternal deletion syndromes (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F105830&amp;token=G%2BkOOgscg7PQzd0gXq5S9xd%2BHuc5IExL4e2c95cxJEuyCnU3EUL%2FTNlXXWj3W5wI&amp;TOPIC_ID=6189" target="_blank">Angelman</a> and <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F176270&amp;token=G%2BkOOgscg7PQzd0gXq5S97PkNhoH%2FzZ%2FJ1m93V6BKty3hYs9iY6TsMlhePjuZVOd&amp;TOPIC_ID=6189" target="_blank">Prader-Willi</a> syndromes) [<a href="#rid31">31</a>] (see  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '15q11-13 maternal deletion syndrome (Angelman syndrome)'</a> and  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '15q11-13 paternal deletion syndrome (Prader-Willi syndrome)'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>16p11.2 deletion syndrome (see  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '16p11.2 deletion syndrome'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>1q21.1 deletion syndrome (see  <a class="medical medical_review" href="/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)", section on 'Distal 1q21.1 deletion syndrome'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>15q13.3 microdeletion syndrome (see  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '15q13.3 deletion syndrome'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>17q21 microdeletion syndrome (see  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '17q21.31 deletion syndrome'</a>)</p><p></p><p class="bulletIndent1">Other microdeletion syndromes are reviewed separately. (See  <a class="medical medical_review" href="/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)"</a> and  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)"</a>.)</p><p></p><p class="headingAnchor" id="H167152331"><span class="h3">Single-gene disorders</span><span class="headingEndMark"> — </span>Monogenic causes of ID can be classified as having autosomal dominant, autosomal recessive, or X-linked inheritance.</p><p class="headingAnchor" id="H1653404563"><span class="h4">Autosomal dominant inheritance</span><span class="headingEndMark"> — </span>De novo mutations in dominantly inherited genes are an important cause of <strong>severe</strong> ID [<a href="#rid6">6,32</a>]. Over 700 genes identified to date are known to cause autosomal dominant ID [<a href="#rid33">33</a>]. Several novel disease genes are identified every year using next generation sequencing (NGS).</p><p>In patients with ID in whom standard genetic tests (including CMA) fail to identify a cause, next-generation WES can identify new mutations in 16 to 29 percent of cases [<a href="#rid17">17,32,34,35</a>]. "Trio" exome analysis (ie, evaluation of the affected child and both parents) is particularly helpful in identifying de novo mutations, which are the most common genetic cause of ID in nonconsanguineous populations [<a href="#rid36">36</a>]. Severe ID could be caused by de novo variants in approximately 35 to 45 percent of affected children [<a href="#rid17">17,32</a>]. (See <a class="local">'Whole exome sequencing'</a> below and  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a>.)</p><p>Some of the genes that have been identified as associated with ID using these techniques include<em> </em><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F614556&amp;token=G%2BkOOgscg7PQzd0gXq5S92WZOezBfGKKLYs6Wo%2BcD%2F4mPr%2BlKbmiKT3YylImDiZH&amp;TOPIC_ID=6189" target="_blank">ARID1B</a><em>,</em> <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F611192&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5Ohg3S577IwzMCQ6cPECzH&amp;TOPIC_ID=6189" target="_blank"><i>ANKRD11</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F159555&amp;token=tEpDslnpc0F0kICl%2Fz7sFQ0zr9utJVpfgcLKS9Z39wgMOEiI%2FfpWWJEvNmLrFjAw&amp;TOPIC_ID=6189" target="_blank"><i>KMT2A</i></a>,<em> </em><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F602926&amp;token=G%2BkOOgscg7PQzd0gXq5S946P%2FQ8jIgu8GW%2FvV8sBfRusgE%2Fq7fluJCa5fUesa%2B0N&amp;TOPIC_ID=6189" target="_blank">STXBP1</a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600473&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyp%2B%2FPMjw0bnR%2BniqZNzAVBt&amp;TOPIC_ID=6189" target="_blank"><i>PURA</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F611386&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6foNERr%2BXKR54IHJtMXxLJ&amp;TOPIC_ID=6189" target="_blank"><i>ADNP</i></a><em>, </em><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F603384&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2FCcQZMeOgJ60%2FMuMfRuQotvFN12YYviffZ%2B0XoNnLl0&amp;TOPIC_ID=6189" target="_blank">SYNGAP1</a><em>, </em><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F182389&amp;token=G%2BkOOgscg7PQzd0gXq5S96RLtGeIiCFlvgYUXm%2FJcawgoNdjglT%2Fn3Q1TfwMT%2BIq&amp;TOPIC_ID=6189" target="_blank">SCN1A</a><em>, </em><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F182390&amp;token=G%2BkOOgscg7PQzd0gXq5S96RLtGeIiCFlvgYUXm%2FJcazj3R489I%2BMg9E9YH2biZwG&amp;TOPIC_ID=6189" target="_blank">SCN2A</a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603309&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrgkMc2tuu0jrlx80wKov21&amp;TOPIC_ID=6189" target="_blank"><i>CDK13</i></a><em>, </em><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F600855&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2Freg2kCAuZKwLQvZ0%2BI0mQ4URXILBphaBz9D0w2ZkES&amp;TOPIC_ID=6189" target="_blank">DYRK1A</a><em>,</em> <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602700&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqrwDGuJP1i1ERcQtQYbXUo&amp;TOPIC_ID=6189" target="_blank"><i>EP300</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602272&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypDEo5P7Bom%2FMt1C8DZh5dp&amp;TOPIC_ID=6189" target="_blank"><i>TCF4</i></a><em>, </em><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F608771&amp;token=G%2BkOOgscg7PQzd0gXq5S90HqoclzQeJILPVbrVM%2F%2FTqQP6fttojEFu8bcakTugHB&amp;TOPIC_ID=6189" target="_blank">MED13L</a><em>,</em> <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F612452&amp;token=G%2BkOOgscg7PQzd0gXq5S93kawsL0kiG%2BTdxpAP9tAodvPX0JgRruVmS1EFPrdrZi&amp;TOPIC_ID=6189" target="_blank">KANSL1</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607001&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqgf7LU2PY6synwVVtvclf0&amp;TOPIC_ID=6189" target="_blank"><i>EHMT1</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601408&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqPIQPSVM%2FTHFLSwwfO4Q6P&amp;TOPIC_ID=6189" target="_blank"><i>KAT6A</i></a><em>, </em><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F605880&amp;token=G%2BkOOgscg7PQzd0gXq5S92J5wxgZVQ0TVD2u6Twj9PKNXoRWgJ%2FssfPEqMLK2dlQ&amp;TOPIC_ID=6189" target="_blank">KAT6B</a>, <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F602113&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2FHJQvw0eniz7sTceRxpKXsgqBmkNtR1RnKkBiaoG3fL&amp;TOPIC_ID=6189" target="_blank">KMT2D</a>, <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F606230&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2BghL1E2QoVl4TDYjrbBQKY1mDQRZju%2F%2Feyv6K1WME%2Ff&amp;TOPIC_ID=6189" target="_blank">SHANK3</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F605515&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyog2nwI8JEW1oencBJ8zgkx&amp;TOPIC_ID=6189" target="_blank"><i>FOXP1</i></a><em>, </em>and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606681&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqT1TJ%2BlRE4I2smzNOemVPN&amp;TOPIC_ID=6189" target="_blank"><i>NSD1</i></a><em> </em>[<a href="#rid17">17,22,34,37,38</a>]. Mutations in these genes often cause other comorbidities such as epilepsy, craniofacial dysmorphism, and/or congenital anomalies.</p><p class="headingAnchor" id="H1034383438"><span class="h4">Autosomal recessive inheritance</span><span class="headingEndMark"> — </span>Autosomal recessive disorders occur particularly in consanguineous families and include many IEM [<a href="#rid11">11,25,26</a>]. Most children with IEM have other features in addition to ID (eg, episodic decompensation, seizures, developmental regression, failure to thrive, abnormal neurologic exam, and/or hepatomegaly). For children with unexplained ID, the yield of metabolic investigations for IEM ranges from 1 to 3 percent  (<a class="graphic graphic_table graphicRef72211" href="/d/graphic/72211.html" rel="external">table 2</a>) [<a href="#rid21">21,24,39</a>]. (See <a class="local">'Metabolic testing'</a> below and  <a class="medical medical_review" href="/d/html/2936.html" rel="external">"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features", section on 'Developmental delay'</a>.)</p><p>Other examples of recessive disorders causing ID include mutations in <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F606709&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2BghL1E2QoVl4TDYjrbBQKbaZ3t6DGgMWCTkbb7CSkzZ&amp;TOPIC_ID=6189" target="_blank">PRSS12</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F616830&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6EhOwOqPNMB90K5gfTvy4P&amp;TOPIC_ID=6189" target="_blank"><i>TANGO2</i></a>, <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F609262&amp;token=G%2BkOOgscg7PQzd0gXq5S90woi3v7XcjNOWY5%2BbSTAWLrez1PBjN7c0XR%2FVH9EIJW&amp;TOPIC_ID=6189" target="_blank">CRBN</a>, <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F610055&amp;token=G%2BkOOgscg7PQzd0gXq5S95tBmSyw%2BvdfQig%2FHMnLNFuSgd8zFGA1360%2B7%2FnCbVsu&amp;TOPIC_ID=6189" target="_blank">CC2D1A</a>, <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F601385&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2FOUAi4NDcBUotLP4lmH5DSqpFxW50ZCnOQt2dy8Yanp&amp;TOPIC_ID=6189" target="_blank">TUSC3</a>, <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F138244&amp;token=G%2BkOOgscg7PQzd0gXq5S96pUpnWibaYfhW%2FvuiucnYRK4KYoCT%2BPD1R%2BA8aC96sH&amp;TOPIC_ID=6189" target="_blank">GRIK2</a><em>,</em> <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F611966&amp;token=G%2BkOOgscg7PQzd0gXq5S911SbBQuAgJliYCdJGO23QBFzR%2Fd86oCZylXAJ8olzaI&amp;TOPIC_ID=6189" target="_blank">TRAPPC9</a>, <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F606494&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2BghL1E2QoVl4TDYjrbBQKY%2BMZ6SdFrKHh4K2QvMNCzA&amp;TOPIC_ID=6189" target="_blank">ST3GAL3</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F605042&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyp6XzcoT17zgyOKKABDRjcq&amp;TOPIC_ID=6189" target="_blank"><i>MED23</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615302&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4lTR%2FKTbMujj0f4MF4D%2BdS&amp;TOPIC_ID=6189" target="_blank"><i>ADAT3</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615262&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5yZfyNcxaOIopATl3%2FsRzj&amp;TOPIC_ID=6189" target="_blank"><i>METTL23</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610299&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4Zt%2FQSFcuHMbT2KywqrPsE&amp;TOPIC_ID=6189" target="_blank"><i>SLC6A17</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610916&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4ragLsRvRnTd5ayEum3SbQ&amp;TOPIC_ID=6189" target="_blank"><i>NSUN2</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604346&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoOkChXWV%2Fo3WdpFUyvVH2N&amp;TOPIC_ID=6189" target="_blank"><i>MAN1B1</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610057&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz76I0v4aaWrxYAHgFQqWMJG&amp;TOPIC_ID=6189" target="_blank"><i>TECR</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604912&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoY7f%2Bb4Eh3%2BBC686YWpght&amp;TOPIC_ID=6189" target="_blank"><i>TAF2</i></a><em>,</em> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609102&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE9LUBro5iWej6m1fE80dW9&amp;TOPIC_ID=6189" target="_blank"><i>FBXO31</i></a> [<a href="#rid40">40-42</a>]. These disorders are increasingly identified by homozygous mapping and WES, where available. (See <a class="local">'Whole exome sequencing'</a> below.)</p><p class="headingAnchor" id="H167152337"><span class="h4">X-linked disorders</span><span class="headingEndMark"> — </span>Mutations resulting in X-linked ID have been reported in &gt;100 genes and account for 5 to 10 percent of ID in males [<a href="#rid43">43-45</a>]. X-linked disorders are very heterogeneous and occur in syndromic or nonsyndromic forms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fragile X syndrome</strong> – The most common X-linked single gene disorder causing ID is <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F300624&amp;token=G%2BkOOgscg7PQzd0gXq5S95p5YXBzP3lIaYBBBbQVxGrBMBPS1rd5LOkn28Mbk%2FrZ&amp;TOPIC_ID=6189" target="_blank">fragile X syndrome</a>, which occurs in approximately 2 to 3 percent of males with ID [<a href="#rid28">28,46</a>]. The prevalence of fragile X syndrome in males with ID is approximately twice that of females (due to variability of expression in females carrying a full mutation as a consequence of variation in X-inactivation). (See <a class="local">'Testing for fragile X syndrome'</a> below and  <a class="medical medical_review" href="/d/html/2924.html" rel="external">"Fragile X syndrome: Clinical features and diagnosis in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MECP2-related disorders</strong> – <em>MECP2</em>-related disorders, including Rett syndrome and <em>MECP2</em> duplication/triplication, are important causes of X-linked ID:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rett syndrome</strong> – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F312750&amp;token=G%2BkOOgscg7PQzd0gXq5S95%2B8WjZe8RlwySN%2B0jZ%2BGKVsxikeLxMclnfWKxbO6oOD&amp;TOPIC_ID=6189" target="_blank">Rett syndrome</a> is a neurodevelopmental disorder caused by <strong>mutations</strong> in <em>MECP2</em> that occurs almost exclusively in females. After a period of initially normal development during the first 6 to 18 months of life, girls experience loss of speech and purposeful hand use, and develop stereotypic hand movements, and gait abnormalities. (See <a class="local">'Testing for specific disorders'</a> below and  <a class="medical medical_review" href="/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MECP2 duplication syndrome</strong> – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F300260&amp;token=G%2BkOOgscg7PQzd0gXq5S95p5YXBzP3lIaYBBBbQVxGoSjp3BLWD6tmsJ%2ByfsgJf8&amp;TOPIC_ID=6189" target="_blank">MECP2 duplication syndrome</a> (also known as Lubs syndrome), is clinically and genetically distinct from Rett syndrome. It is characterized by duplications (or triplication) of the <em>MECP2</em> gene and is a cause of severe to profound ID in males [<a href="#rid47">47</a>]. Females with <em>MECP2</em> duplication are usually asymptomatic, although mild to severe cognitive impairment has been described [<a href="#rid48">48,49</a>]. <em>MECP2</em> duplications account for approximately 1 percent of unexplained X-linked ID [<a href="#rid47">47</a>]. <em>MECP2</em> duplication is suspected in males who have neonatal hypotonia progressing to spasticity, failure to thrive, severe language impairment, severe to profound ID, and seizures. CMA is the recommended test to identify <em>MECP2</em> duplications, as <em>MECP2</em> sequencing tests do not detect duplications. (See <a class="local">'Chromosomal microarray analysis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DDX3X variants</strong> – Pathologic variants in the gene <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300160&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6FQKhZDC9U5Z9zTR%2FvDyvDT&amp;TOPIC_ID=6189" target="_blank"><i>DDX3X</i></a> are responsible for 1 to 3 percent of ID cases in females; affected male individuals have also been reported [<a href="#rid50">50</a>]. ID severity may be mild to severe. Clinical features vary but can include other neurodevelopmental problems (eg, autism spectrum disorder, attention deficit disorder, behavioral problems), abnormal motor tone (hypotonia or spasticity), seizures, structural brain abnormalities, gastrointestinal problems (eg, feeding difficulties, reflux, constipation), and vision problems (eg, refractive errors, strabismus) [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other X-linked disorders</strong> – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F300352&amp;token=G%2BkOOgscg7PQzd0gXq5S95p5YXBzP3lIaYBBBbQVxGo5VRl3Wx1s23rZ6vZgv4GM&amp;TOPIC_ID=6189" target="_blank">X-linked creatine transporter deficiency</a>, caused by pathologic variants in the <em>SLC6A8</em> gene, is characterized by mild to severe ID in males, with speech and motor delay, behavioral abnormalities, and seizures [<a href="#rid52">52</a>]. Elevated ratio of creatine/creatinine in urine with normal plasma levels of creatine and guanidinoacetate are suggestive of the diagnosis, which is confirmed with genetic testing. </p><p></p><p class="bulletIndent1">Some other genetic causes of ID that are X-linked include variants in the genes <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300371&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6H9miA8PpZHB49%2Fuf9uJXcs&amp;TOPIC_ID=6189" target="_blank"><i>ABCD1</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300382&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6EDH8z%2BPfDyRrGoKOFyXs1P&amp;TOPIC_ID=6189" target="_blank"><i>ARX</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300075&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6Fhw3RjpvFUzomP3Ty1zOst&amp;TOPIC_ID=6189" target="_blank"><i>RSK2</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300377&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6FVqpHE2zRL6uNaxaymjrtj&amp;TOPIC_ID=6189" target="_blank"><i>DMD</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300535&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6F5248%2B%2BROWTe%2Bj8YvKIOR7&amp;TOPIC_ID=6189" target="_blank"><i>OCRL</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300011&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6FCp3FnGROrPq3Nt410qM8%2B&amp;TOPIC_ID=6189" target="_blank"><i>ATP7A</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F308840&amp;token=tEpDslnpc0F0kICl%2Fz7sFc1ZyERnYUPWku4Em4XflYy9JL2F8wRDHSbW%2BBjQvfKw&amp;TOPIC_ID=6189" target="_blank"><i>L1CAM</i></a><em>, </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300188&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6FAbc2JMNc63cMa%2FJIcSCyj&amp;TOPIC_ID=6189" target="_blank"><i>MED12</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300032&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6FwYJAwVj3bir29Hh2FBR6T&amp;TOPIC_ID=6189" target="_blank"><i>ATRX</i></a><em> </em>[<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F312080&amp;token=G%2BkOOgscg7PQzd0gXq5S95%2B8WjZe8RlwySN%2B0jZ%2BGKVFyT6juOqcqpb2LPAZ3H5W&amp;TOPIC_ID=6189" target="_blank">Pelizaeus-Merzbacher disease</a> is a rare X-linked hypomyelinating disorder due to duplication in the <em>PLP1</em> gene [<a href="#rid54">54,55</a>]. It is characterized by progressive motor and intellectual deterioration in males. The diagnosis is established with brain magnetic resonance imaging and CMA testing.</p><p></p><p class="headingAnchor" id="H167152356"><span class="h3">Mitochondrial disorders</span><span class="headingEndMark"> — </span>Mitochondrial disorders are a heterogeneous group of diseases that are often associated with ID as well as other neurologic, cardiopulmonary, ophthalmologic, or renal findings. These disorders can be caused by mutations in nuclear genes (autosomal recessive, autosomal dominant, X-linked), or molecular defects in the mitochondrial genome (maternally inherited) [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H167152857"><span class="h2">Environmental causes</span><span class="headingEndMark"> — </span>ID resulting from environmental causes may be due to prenatal, perinatal, and/or postnatal exposures [<a href="#rid57">57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal causes</strong> – Important nongenetic prenatal causes of ID include congenital (TORCH [toxoplasmosis, other (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus, and herpes]) infections and environmental toxins or teratogens (eg, alcohol, lead, mercury, <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a>, radiation exposure). (See  <a class="medical medical_review" href="/d/html/2940.html" rel="external">"Congenital anomalies: Approach to evaluation"</a> and  <a class="medical medical_review" href="/d/html/6011.html" rel="external">"Overview of TORCH infections", section on 'Clinical features of TORCH infections'</a> and  <a class="medical medical_review" href="/d/html/14381.html" rel="external">"Fetal alcohol spectrum disorder: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perinatal causes</strong> – Perinatal abnormalities that may lead to ID include preterm birth, hypoxia, infection, trauma, and intracranial hemorrhage. ID occurs in 5 to 36 percent of surviving infants born at ≤25 weeks gestation [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/4967.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/d/html/5000.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Management and outcome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postnatal causes</strong> – Postnatal and acquired causes of ID may be easier to identify, as they typically occur in a child who was previously normal. Etiologies include accidental or nonaccidental trauma, central nervous system (CNS) hemorrhage, hypoxia (eg, near-drowning), environmental toxins, psychosocial deprivation, malnutrition, intracranial infection, CNS malignancy, or acquired hypothyroidism. If unrecognized and untreated, congenital hypothyroidism may cause intellectual impairment; where newborn screening is available, early screening and treatment has mostly eliminated ID due to congenital hypothyroidism. (See  <a class="medical medical_review" href="/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a>.)</p><p></p><p class="bulletIndent1">Some children with ID may have an etiology that is multifactorial. In these cases, multiple conditions or exposures may act simultaneously or at different times. The relative extent or contribution of multiple conditions or toxins upon outcomes is not known, although insults at younger developmental ages have greater impact.</p><p></p><p class="headingAnchor" id="H6"><span class="h1">APPROACH TO DIAGNOSTIC TESTING</span><span class="headingEndMark"> — </span>Selection and sequence of diagnostic testing to identify a cause in children with ID is guided by a detailed history (including family history), thorough physical examination (including neurologic examination and evaluation for dysmorphic features), and the availability of the specific tests [<a href="#rid3">3,9,23</a>]. A collaborative approach that includes parent participation in the child's evaluation is important. Tests may vary across clinical settings and among nations, especially where screening programs differ [<a href="#rid59">59</a>]. Factors such as the cost-benefit, cost-effectiveness, and the evidence base for specific, sequential, or stepwise testing in evaluation may be considered.</p><p>The following sections review the approach to diagnostic testing in children with ID. The approach may differ in children with ID that is associated with autism, cerebral palsy, epilepsy, or sensory disorders (blindness, deafness). These conditions are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6169.html" rel="external">"Cerebral palsy: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6199.html" rel="external">"Seizures and epilepsy in children: Classification, etiology, and clinical features"</a> and  <a class="medical medical_review" href="/d/html/6308.html" rel="external">"Hearing loss in children: Etiology"</a>.)</p><p class="headingAnchor" id="H1313366806"><span class="h2">Goals of the evaluation</span><span class="headingEndMark"> — </span>The evaluation is aimed at identifying a particular cause so as to provide more information to the family about the associated prognosis, comorbidities, anticipation of future needs, and whether any specific treatment is available. With the exception of treatable metabolic disorders, most causes of ID do not have specific treatments to rectify the cause. Genetic causes may have implications for future pregnancies, and there may also be reproductive implications for the extended family, which should be addressed with genetic counseling. Even if a specific diagnosis cannot be found, excluding certain disorders may be helpful for the parents and other family members.</p><p class="headingAnchor" id="H988137389"><span class="h2">Testing for specific disorders</span><span class="headingEndMark"> — </span>Children with dysmorphic features or other characteristics that suggest a particular syndrome or disorder should undergo specific testing to confirm or rule out that disorder  (<a class="graphic graphic_algorithm graphicRef95374" href="/d/graphic/95374.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef107958" href="/d/graphic/107958.html" rel="external">table 3</a>).</p><p>Some examples of suspected disorders that are associated with characteristic findings for which specific tests are recommended as the initial step are discussed here. Additional examples are provided in the table  (<a class="graphic graphic_table graphicRef107958" href="/d/graphic/107958.html" rel="external">table 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Down syndrome or other common aneuploidy</strong> – For children with clinical features suggesting Down syndrome or other common aneuploidy (trisomy 18 or a sex chromosome aneuploidy such as Klinefelter [47,XXY]), we suggest a G-banded karyotype analysis. (See <a class="local">'Karyotype analysis'</a> below and  <a class="medical medical_review" href="/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities"</a> and  <a class="medical medical_review" href="/d/html/16974.html" rel="external">"Sex chromosome abnormalities"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fragile X syndrome</strong> – Fragile X syndrome (full <em>FMR1</em> mutation) should be suspected in males with moderate to severe ID, macrocephaly, large ears, enlarged testes after puberty, perseverative speech, and gaze aversion. Males with unexplained ID <strong>and</strong> a family history of ID should also be evaluated for the syndrome. Females with characteristic clinical features or a family history of ID also should be tested for fragile X syndrome because females with full <em>FMR1</em> mutation present with ID in approximately half of the cases. (See <a class="local">'Testing for fragile X syndrome'</a> below and  <a class="medical medical_review" href="/d/html/2924.html" rel="external">"Fragile X syndrome: Clinical features and diagnosis in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rett syndrome</strong> – Rett syndrome should be suspected in girls with unexplained moderate to severe ID who had normal development during the first six months of life and then experienced a period of regression or developmental stagnation usually beginning in the second year of life, especially if there are stereotypic hand movements. (See  <a class="medical medical_review" href="/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inborn errors of metabolism</strong> – ID is a clinical feature of some inborn errors of metabolism (IEM). Most affected children have other manifestations of metabolic disease, such as episodic decompensation, seizures, developmental regression, failure to thrive, abnormal neurologic exam, and/or hepatomegaly. Screening programs in the United States identify many newborns with IEM. (See  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder", section on 'Newborn screening'</a>.)</p><p></p><p class="bulletIndent1">The results of newborn screening for metabolic disorders should be reviewed as part of the initial evaluation in all children with ID. Additional testing should be performed if these results are not available, or in children with a positive family history of metabolic disorders, parental consanguinity, episodic decompensation, or developmental regression. The presence of these features increases the likelihood of identification of a disorder compared with nonselective screening [<a href="#rid60">60</a>]. (See <a class="local">'Metabolic testing'</a> below.)</p><p></p><p class="bulletIndent1">The approach to evaluating children with suspected metabolic disorders is reviewed separately. (See  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothyroidism</strong> – Thyroid testing should be performed in infants and children with clinical features suggestive of hypothyroidism (eg, decelerating growth velocity/short stature, cold intolerance, feeding problems, puffy facies, macroglossia, large fontanels, hypotonia, dry skin, and prolonged jaundice). (See  <a class="medical medical_review" href="/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">In addition, thyroid testing is recommended routinely for infants and children presenting with ID in countries without newborn screening programs for congenital hypothyroidism. In these areas, unrecognized congenital hypothyroidism is a more common cause of ID. Most affected patients have additional systemic signs of hypothyroidism.</p><p></p><p class="bulletIndent1">In countries where newborn screening for hypothyroidism is routinely performed, congenital hypothyroidism is an uncommon cause of ID.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscular dystrophy</strong> – For boys with unexplained global developmental delay (GDD) or ID with proximal muscle weakness, we suggest measurement of serum creatine kinase to screen for Duchenne muscular dystrophy. If the creatine kinase is elevated, specific genetic testing is then performed. Boys with Duchenne muscular dystrophy may present with unexplained GDD/ID; screening is appropriate for boys with clinical features that suggest this diagnosis [<a href="#rid61">61,62</a>]. Early identification of this disorder enables early intervention and family counseling. Becker muscular dystrophy also may be associated with ID, but the muscular dysfunction tends to be milder. (See  <a class="medical medical_review" href="/d/html/6149.html" rel="external">"Duchenne and Becker muscular dystrophy: Clinical features and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H18781212"><span class="h2">Unexplained ID</span><span class="headingEndMark"> — </span>If no specific disorder is clinically suspected or if initial testing for specific disorders is nondiagnostic, then genetic testing for idiopathic or unexplained ID is recommended, starting with a chromosomal microarray analysis (CMA)  (<a class="graphic graphic_algorithm graphicRef95374" href="/d/graphic/95374.html" rel="external">algorithm 1</a>) [<a href="#rid2">2,3,9,23</a>].</p><p class="headingAnchor" id="H4155392243"><span class="h3">Rationale for genetic testing</span><span class="headingEndMark"> — </span>Genetic tests are recommended for unexplained ID because they can provide diagnostic and prognostic information and allow for informative genetic counseling. In addition, genetic testing may identify conditions that require further medical evaluation or management.</p><p>A genetic disorder is suggested when unexplained ID occurs in combination with one or more of the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of consanguinity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of ID</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal history of multiple miscarriages or family history of infant deaths</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital/visceral anomalies (eg, hearing loss, visual problems, congenital heart defects, vascular abnormalities, skeletal abnormalities, endocrine problems, central nervous system [CNS] malformations, seizures, microcephaly or macrocephaly, stroke, intestinal atresia/stenosis, hepatomegaly, splenomegaly, or urogenital anomalies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysmorphic features</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure to thrive or growth abnormalities (short or tall stature)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal tone (eg, hypotonia, spasticity, dystonia)</p><p></p><p>Although diagnostic tests for chromosome abnormalities and single gene disorders have the highest yield when these findings are present, testing has a diagnostic yield even if such features are absent. The diagnostic yields of different tests or testing approaches are summarized in the table  (<a class="graphic graphic_table graphicRef72211" href="/d/graphic/72211.html" rel="external">table 2</a>); the reported diagnostic yields are estimated based on meta-analysis of different patient groups rather than representative population-based samples [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H18781219"><span class="h3">Chromosomal microarray analysis</span><span class="headingEndMark"> — </span>CMA is preferred over G-banded karyotype analysis or subtelomeric fluorescence in situ hybridization (FISH) as the first-line genetic test for unexplained ID due to its higher sensitivity and thus greater diagnostic yield  (<a class="graphic graphic_table graphicRef72211" href="/d/graphic/72211.html" rel="external">table 2</a>) [<a href="#rid2">2,23,63-66</a>]. CMA is also known as molecular karyotyping, microarray-based genomic copy-number analysis, or array-based comparative genomic hybridization (aCGH). (See  <a class="medical medical_review" href="/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Array comparative genomic hybridization'</a>.)</p><p>The use of CMA leads to a genetic diagnosis in 15 to 20 percent of patients with unexplained ID  (<a class="graphic graphic_table graphicRef72211" href="/d/graphic/72211.html" rel="external">table 2</a>). The higher yield of CMA compared with G-banded karyotype analysis or FISH is primarily because of its sensitivity for submicroscopic copy-number variations (ie, deletions and duplications) [<a href="#rid67">67</a>]. In a meta-analysis of 33 studies of patients with ID, autism spectrum disorder, or multiple congenital anomalies, the average diagnostic yield of CMA was 12 percent [<a href="#rid23">23</a>]. In another study of more than 35,000 patients with ID, CMA detected a pathogenic abnormality in nearly 19 percent of patients [<a href="#rid68">68</a>].</p><p>CMA does not detect point mutations (sequence variants) responsible for single-gene disorders. In addition, CMA will not identify balanced translocations, such as translocations or inversions and may not detect low-level mosaicism, but these are relatively infrequent causes of abnormal phenotypes in this population.</p><p>Clinicians should be aware that there are different platforms for CMA studies. Oligonucleotide-based arrays provide a superb means of detecting DNA copy-number changes, including single exon deletions [<a href="#rid69">69,70</a>]. There are a large number of designs of CMA with different levels of resolution (from approximately 1 Mb to several kb). The arrays might be whole-genome arrays, designed to cover the entire genome, or targeted arrays, which target known disease-causing regions.</p><p>Single nucleotide polymorphism (SNP) arrays can detect copy-number changes, as well as long contiguous stretches of copy-number neutral regions of absence of heterozygosity, that can be associated with uniparental disomy or parental consanguinity. Both of these findings increase the risk for autosomal recessive conditions. In addition, SNP arrays detect triploidy, low-level mosaicism, and chimerism [<a href="#rid71">71</a>]. Combined oligonucleotide/SNP arrays are also available to pool the advantages of each method [<a href="#rid72">72</a>].</p><p>Deciphering variants of uncertain clinical significance may be challenging. Interpretation of a CMA result requires expert review to determine whether a copy-number variant is clinically significant. In some cases, testing of the patient's parents is necessary to fully assess the clinical significance of a result to enable appropriate genetic counseling [<a href="#rid23">23,73</a>]. Incomplete penetrance and variable expressivity are frequently observed for several disorders associated with genomic microdeletions and microduplications. Carrier parents may be completely healthy for some of these disorders, such as 15q13.3 deletion, 1q21.1 deletion, and <em>NRXN1</em> deletion.</p><p>If the CMA testing result is normal or yields a known benign variant, then further evaluation using specific tests may be considered, as recommended in a consensus statement [<a href="#rid23">23</a>]. If CMA fails to find a cause of ID, whole exome sequencing (WES) can be applied to identify causative mutations. (See <a class="local">'Whole exome sequencing'</a> below.)</p><p class="headingAnchor" id="H31558952"><span class="h3">Testing for fragile X syndrome</span><span class="headingEndMark"> — </span>Fragile X syndrome is caused by an abnormal expansion mutation of a CGG triplet repeat in the <em>FMR1</em> gene (typically &gt;200) and is the most prevalent form of inherited ID [<a href="#rid74">74</a>]. Most affected males and approximately one-half of females with a full fragile X mutation have ID. Males generally have moderate to severe ID and may not have the characteristic appearance; affected females tend to have mild ID. (See  <a class="medical medical_review" href="/d/html/2924.html" rel="external">"Fragile X syndrome: Clinical features and diagnosis in children and adolescents"</a>.)</p><p>Selection criteria for fragile X testing vary among authorities. Most experts recommend fragile X testing for all children in the following groups  (<a class="graphic graphic_table graphicRef72211" href="/d/graphic/72211.html" rel="external">table 2</a>) [<a href="#rid23">23,74</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Males and females with ID and clinical features suggesting fragile X syndrome (eg, macrocephaly, large ears, enlarged testes after puberty in males, perseverative speech, and poor eye contact)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males and females with unexplained ID or developmental delay <strong>and</strong> a family history of ID</p><p></p><p>In addition, many authorities suggest fragile X testing for all children with the following characteristics: </p><p class="bulletIndent1"><span class="glyph">●</span>Males and females with ID whose initial microarray testing is normal or benign [<a href="#rid23">23</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Males and females with unexplained ID (because of a 1 to 3 percent diagnostic yield [<a href="#rid46">46</a>])</p><p class="bulletIndent1"><span class="glyph">●</span>Males and females with unexplained autism [<a href="#rid74">74,75</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Males and females with borderline ID [<a href="#rid74">74</a>]</p><p></p><p>In many institutions, fragile X testing is done concurrently with CMA for the evaluation of ID in children.</p><p class="headingAnchor" id="H1977480125"><span class="h3">Karyotype analysis</span><span class="headingEndMark"> — </span>G-banded karyotype analysis should be reserved for the following circumstances [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A common aneuploidy is suspected based on clinical findings (eg, Down syndrome, trisomy 18, or a sex chromosome aneuploidy). (See <a class="local">'Testing for specific disorders'</a> above and  <a class="medical medical_review" href="/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on 'Numeric abnormalities'</a> and  <a class="medical medical_review" href="/d/html/13921.html" rel="external">"Clinical features, diagnosis, and management of Klinefelter syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is concern for balanced translocation (eg, maternal history of frequent miscarriages, or a family history of translocation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMA is unavailable.</p><p></p><p>G-banded karyotype analysis detects major structural abnormalities and will not detect smaller regions of DNA gain or loss. (See  <a class="medical medical_review" href="/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Chromosomal analysis'</a>.)</p><p class="headingAnchor" id="H941038336"><span class="h3">Metabolic testing</span><span class="headingEndMark"> — </span>ID is a clinical feature of some IEM. Most affected children have other manifestations of metabolic disease, such as episodic decompensation, seizures, developmental regression, failure to thrive, or abnormal neurologic exam. In addition, screening programs in the United States identify many newborns with IEM.</p><p>For children with unexplained ID, the yield of routine metabolic investigations is low, ranging from 0.8 to 3 percent  (<a class="graphic graphic_table graphicRef72211" href="/d/graphic/72211.html" rel="external">table 2</a>), but the potential for improved outcomes after diagnosis and treatment is high [<a href="#rid2">2</a>]. These laboratory tests are appropriate for children with ID and clinical features suggestive of metabolic disease, as outlined above.</p><p>To perform metabolic screening, concentrations of plasma amino acids, urine organic acids, serum ammonia, and lactate are most often measured; very long-chain fatty acids and carnitine may also be measured on blood samples [<a href="#rid23">23</a>]. Electrolytes are measured to detect acidosis. If further metabolic testing is performed and guided by a specialist, the diagnostic yield increases to at least 3 percent, particularly in children with suggestive clinical features [<a href="#rid46">46</a>]. Other possible tests include urine and plasma creatine and guanidinoacetate (for creatine synthesis and transport disorders), blood homocysteine and transferrin electrophoresis, urine glycosaminoglycans, urine purines and pyrimidines, and oligosaccharides [<a href="#rid2">2,46,59</a>]. (See  <a class="medical medical_review" href="/d/html/2936.html" rel="external">"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features", section on 'Developmental delay'</a>.)</p><p class="headingAnchor" id="H488491940"><span class="h3">Whole exome sequencing</span><span class="headingEndMark"> — </span>WES should be considered for patients with moderate to severe ID in whom other standard tests (including CMA) have failed to identify the cause  (<a class="graphic graphic_algorithm graphicRef95374" href="/d/graphic/95374.html" rel="external">algorithm 1</a>). The diagnostic yield of WES in this setting is approximately 16 to 33 percent [<a href="#rid17">17,22,32,34,35,76</a>]. The diagnostic yield is likely lower in patients with mild ID without additional findings and the role of WES testing in this population is not defined.</p><p>WES testing should be performed with consultation of a clinical geneticist and should include appropriate pretest counseling to discuss the risk of incidental findings unrelated to the child's ID that may be medically actionable (eg, <em>BRCA1</em> or <em>BRCA2</em> mutation) [<a href="#rid77">77</a>]. Incidental findings can be minimized if a focused analysis is conducted. (See <a class="local">'Referral and follow-up'</a> below and  <a class="medical medical_review" href="/d/html/96539.html" rel="external">"Secondary findings from genetic testing"</a>.)</p><p>Due to the falling costs of sequencing and its high diagnostic yield, WES is rapidly becoming a clinical tool for the evaluation of ID, especially at specialty centers [<a href="#rid36">36</a>]. Adoption of WES testing into the diagnostic process will depend on its cost, availability, access to expert interpretation, and the allocation of resources within each health care setting [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Practical issues'</a>.)</p><p class="headingAnchor" id="H3949415764"><span class="h3">Fluorescence in situ hybridization (FISH)</span><span class="headingEndMark"> — </span>Chromosomal rearrangements in the gene-rich subtelomeric region are identified in approximately 4 to 6 percent of children with ID [<a href="#rid79">79</a>]. Molecular screening using FISH of subtelomeric probes was used widely in the past to identify these abnormalities; however, CMA has replaced FISH as the test of choice, since the majority of diagnostic CMA arrays offer dense coverage of subtelomeric regions  (<a class="graphic graphic_table graphicRef72211" href="/d/graphic/72211.html" rel="external">table 2</a>). FISH may still be substituted if array diagnosis is not available or if a specific telomeric disorder (eg, DiGeorge syndrome, Cri-du-chat syndrome) is strongly suspected clinically. (See  <a class="medical medical_review" href="/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Fluorescence in situ hybridization'</a> and  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on '5p deletion syndrome (cri-du-chat syndrome)'</a> and  <a class="medical medical_review" href="/d/html/83396.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H21442566"><span class="h3">Other tests</span></p><p class="headingAnchor" id="H2810354544"><span class="h4">Lead screening</span><span class="headingEndMark"> — </span>Blood lead testing should be performed if the child has not had prior lead screening. In addition, lead screening should be performed if any of the following risk factors for lead exposure are present: </p><p class="bulletIndent1"><span class="glyph">●</span>Persistent mouthing behavior and pica</p><p class="bulletIndent1"><span class="glyph">●</span>Living in a house or child care facility built before 1950</p><p class="bulletIndent1"><span class="glyph">●</span>Recent immigration or home renovation</p><p class="bulletIndent1"><span class="glyph">●</span>Ethnic remedies, and some parental occupations (smelting, soldering, and auto body repair)</p><p></p><p>Although lead toxicity is an uncommon cause of ID in the United States, children with ID are at increased risk for lead exposure, partly because they progress slower and spend longer in stages where mouthing behavior is common. In one report, blood lead levels &gt;10 mcg/dL occurred in a greater proportion of children with behavioral and/or developmental problems than in controls (12 versus 0.7 percent) [<a href="#rid80">80</a>].</p><p>Lead is the most common environmental neurotoxin. Lead exposure can harm cognitive function at any level [<a href="#rid81">81</a>]. Childhood lead poisoning is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6491.html" rel="external">"Childhood lead poisoning: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2872.html" rel="external">"Screening tests in children and adolescents", section on 'Lead poisoning'</a>.)</p><p class="headingAnchor" id="H11"><span class="h4">Neuroimaging</span><span class="headingEndMark"> — </span>We suggest neuroimaging be obtained (preferably with magnetic resonance imaging [MRI]) if there are concerning features in the history (eg, seizures, progressive or degenerative neurologic symptoms) or abnormal findings on physical examination (eg, microcephaly, macrocephaly, focal neurologic deficits). Consultation with a pediatric neurologist may be warranted in these cases. This approach is consistent with recommendations of the American Academy of Neurology, the Child Neurology Society, and the American Academy of Pediatrics [<a href="#rid2">2,9</a>].</p><p>MRI is the preferred imaging modality; however, computed tomography may be acceptable if MRI is not available. Potential radiation exposure and risk of sedation should be considered as part of informed decision-making.</p><p>Abnormal findings on neuroimaging are seen in approximately 30 percent of children with GDD/ID; however, most abnormalities are nonspecific, and often do not lead to a specific diagnosis or alter clinical management [<a href="#rid2">2,60,82,83</a>]. Common findings include CNS malformations, white matter abnormalities, and cerebral atrophy. The yield is higher among children with specific physical features such as microcephaly, epilepsy, or abnormal motor signs [<a href="#rid8">8,83</a>].</p><p class="headingAnchor" id="H1244996017"><span class="h1">REFERRAL AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Referral to a pediatric geneticist is valuable for many children with ID, especially those with moderate to severe ID who remain undiagnosed despite appropriate investigation. The consultation may yield a definitive diagnosis and can facilitate genetic counseling for the family and appropriate management of the patient.</p><p>Children with syndromic features and/or abnormal results of initial genetic testing (which may include chromosomal microarray analysis, fragile X testing, G-band karyotype, and/or metabolic studies) should promptly be referred to a clinical geneticist for further evaluation and counseling. In addition, clinicians should consult geneticists early in the evaluation of unexplained ID, particularly if the initial work up is negative.</p><p>Depending on the cost and the available resources, clinical geneticists can recommend whole exome sequencing (WES) after appropriate pretest counseling. All families should undergo pretest counseling with a formal informed consent before WES is undertaken [<a href="#rid77">77</a>]. In a child with suspected genetic disorder and a nondiagnostic WES study, re-evaluation is recommended every few years, in view of the expanding scientific advances concerning novel genetic disorders of ID. (See  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Intellectual disability (ID) is a neurodevelopmental disorder with multiple etiologies that is characterized by deficits in intellectual and adaptive functioning that affect at least one adaptive domain (conceptual, social, and/or practical) with varying severity  (<a class="graphic graphic_table graphicRef90174 graphicRef95384" href="/d/graphic/90174.html" rel="external">table 1A-B</a>). In the general population, the prevalence of ID is approximately 1 percent. ID is mild in approximately 85 percent of affected individuals. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above and  <a class="medical medical_review" href="/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A genetic cause can be identified in &gt;50 percent of cases of ID in populations referred for specialty evaluation. Down syndrome is the single most common genetic cause of ID. X-linked disorders (including fragile X syndrome) account for approximately 5 to 10 percent of ID in males. De novo dominant mutations are an important cause of severe ID. (See <a class="local">'Genetic causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nongenetic prenatal causes of ID include congenital infections, and teratogens such as alcohol, lead, and <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a>. Perinatal abnormalities account for up to 5 percent of ID and include preterm birth, hypoxia, infection, trauma, and intracranial hemorrhage. Postnatal and acquired causes of ID include accidental or nonaccidental trauma, central nervous system (CNS) hemorrhage, congenital hypothyroidism, hypoxia (eg, near-drowning), environmental toxins, psychosocial deprivation, malnutrition, intracranial infection, and CNS malignancy. (See <a class="local">'Environmental causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Selection and sequence of diagnostic tests in children with ID is guided by individual patient characteristics and the availability of specific tests. The evaluation begins with a detailed medical history (including review of newborn screening results), family history, and thorough physical examination (including neurologic examination and evaluation for dysmorphic features). (See <a class="local">'Approach to diagnostic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with ID, particularly those with moderate to severe ID, should be offered referral for a genetics consultation. Consultation may yield a definitive diagnosis and facilitate counseling and condition-specific management and support. (See <a class="local">'Referral and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children with features suggestive of a specific diagnosis, the initial evaluation involves testing for the specific syndrome or disorder  (<a class="graphic graphic_table graphicRef107958" href="/d/graphic/107958.html" rel="external">table 3</a>). (See <a class="local">'Testing for specific disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with unexplained ID (ie, those without features suggestive of a specific diagnosis and those with negative results of specific tests), we suggest the following testing for genetic and metabolic disorders  (<a class="graphic graphic_algorithm graphicRef95374" href="/d/graphic/95374.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chromosomal microarray (CMA) is the first-line genetic test for unexplained ID and detects a cause in 15 to 20 percent of the cases of ID  (<a class="graphic graphic_table graphicRef72211" href="/d/graphic/72211.html" rel="external">table 2</a>). Abnormalities that can be detected by CMA include submicroscopic deletions and duplications. If CMA is not available, then G-banded karyotype and fluorescence in situ hybridization testing may be applied instead. (See <a class="local">'Chromosomal microarray analysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with features that suggest the possibility of a balanced translocation in the family (eg, maternal history of frequent miscarriages or a family history of chromosomal abnormalities), G-banded karyotyping should be performed either before or in addition to CMA. (See <a class="local">'Karyotype analysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the CMA is normal or benign, fragile X testing should be performed (if not already done). (See <a class="local">'Testing for fragile X syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood lead testing should be performed if the child has not had prior lead screening and/or risk factors for exposure are present (eg, persistent mouthing behavior, pica, living in a house or child care facility built before 1950, recent immigration or home renovation, ethnic remedies, and some parental occupations [smelting, soldering, and auto body repair]). (See <a class="local">'Lead screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuroimaging should be performed if there are concerning features in the history (eg, seizures, progressive or degenerative neurologic symptoms) or abnormal findings on physical examination (eg, microcephaly, macrocephaly, focal neurologic deficits). Magnetic resonance imaging is the preferred imaging modality. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the above testing is negative, genetics consultation can guide further evaluation, which may include metabolic testing (if not done previously) and/or whole exome sequencing (depending on availability). (See <a class="local">'Metabolic testing'</a> above and <a class="local">'Whole exome sequencing'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, Arlington 2013.</li><li><a class="nounderline abstract_t">Moeschler JB, Shevell M, Committee on Genetics. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics 2014; 134:e903.</a></li><li><a class="nounderline abstract_t">Szymanski L, King BH. Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999; 38:5S.</a></li><li><a class="nounderline abstract_t">Szymanski L, King BH. Summary of the Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Mental Retardation and Comorbid Mental Disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1999; 38:1606.</a></li><li class="breakAll">Harris JC. The classification of intellectual disability. In: Intellectual disability: Understanding its development, causes, classification, evaluation, and treatment, Oxford University Press, New York 2006. p.42.</li><li><a class="nounderline abstract_t">Veltman JA, Brunner HG. De novo mutations in human genetic disease. Nat Rev Genet 2012; 13:565.</a></li><li><a class="nounderline abstract_t">Maulik PK, Mascarenhas MN, Mathers CD, et al. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil 2011; 32:419.</a></li><li><a class="nounderline abstract_t">Moeschler JB, Shevell M, American Academy of Pediatrics Committee on Genetics. Clinical genetic evaluation of the child with mental retardation or developmental delays. Pediatrics 2006; 117:2304.</a></li><li><a class="nounderline abstract_t">Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology 2003; 60:367.</a></li><li><a class="nounderline abstract_t">Lai DC, Tseng YC, Hou YM, Guo HR. Gender and geographic differences in the prevalence of intellectual disability in children: analysis of data from the national disability registry of Taiwan. Res Dev Disabil 2012; 33:2301.</a></li><li><a class="nounderline abstract_t">Kaufman L, Ayub M, Vincent JB. The genetic basis of non-syndromic intellectual disability: a review. J Neurodev Disord 2010; 2:182.</a></li><li><a class="nounderline abstract_t">Chiurazzi P, Pirozzi F. Advances in understanding - genetic basis of intellectual disability. F1000Res 2016; 5.</a></li><li><a class="nounderline abstract_t">Croen LA, Grether JK, Selvin S. The epidemiology of mental retardation of unknown cause. Pediatrics 2001; 107:E86.</a></li><li><a class="nounderline abstract_t">Chapman DA, Scott KG, Mason CA. Early risk factors for mental retardation: role of maternal age and maternal education. Am J Ment Retard 2002; 107:46.</a></li><li><a class="nounderline abstract_t">Emerson E. Poverty and people with intellectual disabilities. Ment Retard Dev Disabil Res Rev 2007; 13:107.</a></li><li><a class="nounderline abstract_t">Leonard H, Glasson E, Nassar N, et al. Autism and intellectual disability are differentially related to sociodemographic background at birth. PLoS One 2011; 6:e17875.</a></li><li><a class="nounderline abstract_t">Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 2012; 380:1674.</a></li><li><a class="nounderline abstract_t">Moeschler JB. Genetic evaluation of intellectual disabilities. Semin Pediatr Neurol 2008; 15:2.</a></li><li><a class="nounderline abstract_t">Willemsen MH, Kleefstra T. Making headway with genetic diagnostics of intellectual disabilities. Clin Genet 2014; 85:101.</a></li><li><a class="nounderline abstract_t">Leonard H, Wen X. The epidemiology of mental retardation: challenges and opportunities in the new millennium. Ment Retard Dev Disabil Res Rev 2002; 8:117.</a></li><li><a class="nounderline abstract_t">van Karnebeek CD, Scheper FY, Abeling NG, et al. Etiology of mental retardation in children referred to a tertiary care center: a prospective study. Am J Ment Retard 2005; 110:253.</a></li><li><a class="nounderline abstract_t">Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 2015; 519:223.</a></li><li><a class="nounderline abstract_t">Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86:749.</a></li><li><a class="nounderline abstract_t">Engbers HM, Berger R, van Hasselt P, et al. Yield of additional metabolic studies in neurodevelopmental disorders. Ann Neurol 2008; 64:212.</a></li><li><a class="nounderline abstract_t">van Karnebeek CD, Shevell M, Zschocke J, et al. The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource. Mol Genet Metab 2014; 111:428.</a></li><li><a class="nounderline abstract_t">Chelly J, Khelfaoui M, Francis F, et al. Genetics and pathophysiology of mental retardation. Eur J Hum Genet 2006; 14:701.</a></li><li><a class="nounderline abstract_t">Chiurazzi P, Oostra BA. Genetics of mental retardation. Curr Opin Pediatr 2000; 12:529.</a></li><li><a class="nounderline abstract_t">Rauch A, Hoyer J, Guth S, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 2006; 140:2063.</a></li><li><a class="nounderline abstract_t">Merla G, Brunetti-Pierri N, Micale L, Fusco C. Copy number variants at Williams-Beuren syndrome 7q11.23 region. Hum Genet 2010; 128:3.</a></li><li><a class="nounderline abstract_t">Elsea SH, Girirajan S. Smith-Magenis syndrome. Eur J Hum Genet 2008; 16:412.</a></li><li><a class="nounderline abstract_t">Buiting K. Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C Semin Med Genet 2010; 154C:365.</a></li><li><a class="nounderline abstract_t">de Ligt J, Willemsen MH, van Bon BW, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med 2012; 367:1921.</a></li><li><a class="nounderline abstract_t">Vissers LE, Gilissen C, Veltman JA. Genetic studies in intellectual disability and related disorders. Nat Rev Genet 2016; 17:9.</a></li><li><a class="nounderline abstract_t">Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 2013; 369:1502.</a></li><li><a class="nounderline abstract_t">Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 2014; 312:1870.</a></li><li><a class="nounderline abstract_t">Monroe GR, Frederix GW, Savelberg SM, et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genet Med 2016; 18:949.</a></li><li><a class="nounderline abstract_t">Kilic E, Cetinkaya A, Utine GE, Boduroğlu K. A Diagnosis to Consider in Intellectual Disability: Mowat-Wilson Syndrome. J Child Neurol 2016; 31:913.</a></li><li><a class="nounderline abstract_t">Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature 2017; 542:433.</a></li><li><a class="nounderline abstract_t">van Karnebeek CD, Jansweijer MC, Leenders AG, et al. Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. Eur J Hum Genet 2005; 13:6.</a></li><li><a class="nounderline abstract_t">Reuter MS, Tawamie H, Buchert R, et al. Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families With Neurodevelopmental Disorders. JAMA Psychiatry 2017; 74:293.</a></li><li><a class="nounderline abstract_t">Khan MA, Khan S, Windpassinger C, et al. The Molecular Genetics of Autosomal Recessive Nonsyndromic Intellectual Disability: a Mutational Continuum and Future Recommendations. Ann Hum Genet 2016; 80:342.</a></li><li><a class="nounderline abstract_t">Lalani SR, Liu P, Rosenfeld JA, et al. Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations. Am J Hum Genet 2016; 98:347.</a></li><li><a class="nounderline abstract_t">Ropers HH. Genetics of early onset cognitive impairment. Annu Rev Genomics Hum Genet 2010; 11:161.</a></li><li class="breakAll">Stevenson RE, Charles E, Schwartz R, Rogers RC. Atlas of X-Linked Intellectual Disability Syndromes, Oxford University Press, New York 2012.</li><li><a class="nounderline abstract_t">Lubs HA, Stevenson RE, Schwartz CE. Fragile X and X-linked intellectual disability: four decades of discovery. Am J Hum Genet 2012; 90:579.</a></li><li><a class="nounderline abstract_t">Michelson DJ, Shevell MI, Sherr EH, et al. Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2011; 77:1629.</a></li><li><a class="nounderline abstract_t">Lugtenberg D, Kleefstra T, Oudakker AR, et al. Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet 2009; 17:444.</a></li><li><a class="nounderline abstract_t">Grasshoff U, Bonin M, Goehring I, et al. De novo MECP2 duplication in two females with random X-inactivation and moderate mental retardation. Eur J Hum Genet 2011; 19:507.</a></li><li><a class="nounderline abstract_t">Scott Schwoerer J, Laffin J, Haun J, et al. MECP2 duplication: possible cause of severe phenotype in females. Am J Med Genet A 2014; 164A:1029.</a></li><li><a class="nounderline abstract_t">Levy T, Siper PM, Lerman B, et al. DDX3X Syndrome: Summary of Findings and Recommendations for Evaluation and Care. Pediatr Neurol 2023; 138:87.</a></li><li><a class="nounderline abstract_t">Snijders Blok L, Madsen E, Juusola J, et al. Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling. Am J Hum Genet 2015; 97:343.</a></li><li><a class="nounderline abstract_t">van de Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, et al. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. J Med Genet 2013; 50:463.</a></li><li><a class="nounderline abstract_t">Stevenson RE, Schwartz CE. X-linked intellectual disability: unique vulnerability of the male genome. Dev Disabil Res Rev 2009; 15:361.</a></li><li><a class="nounderline abstract_t">Hoffman-Zacharska D, Mierzewska H, Szczepanik E, et al. The spectrum of PLP1 gene mutations in patients with the classical form of the Pelizaeus-Merzbacher disease. Med Wieku Rozwoj 2013; 17:293.</a></li><li><a class="nounderline abstract_t">Hoffman-Zacharska D, Kmieć T, Poznański J, et al. Mutations in the PLP1 gene residue p. Gly198 as the molecular basis of Pelizeaus-Merzbacher phenotype. Brain Dev 2013; 35:877.</a></li><li><a class="nounderline abstract_t">Wong LJ. Molecular genetics of mitochondrial disorders. Dev Disabil Res Rev 2010; 16:154.</a></li><li><a class="nounderline abstract_t">Huang J, Zhu T, Qu Y, Mu D. Prenatal, Perinatal and Neonatal Risk Factors for Intellectual Disability: A Systemic Review and Meta-Analysis. PLoS One 2016; 11:e0153655.</a></li><li><a class="nounderline abstract_t">Jarjour IT. Neurodevelopmental outcome after extreme prematurity: a review of the literature. Pediatr Neurol 2015; 52:143.</a></li><li><a class="nounderline abstract_t">McDonald L, Rennie A, Tolmie J, et al. Investigation of global developmental delay. Arch Dis Child 2006; 91:701.</a></li><li><a class="nounderline abstract_t">Shevell MI, Majnemer A, Rosenbaum P, Abrahamowicz M. Etiologic yield of subspecialists' evaluation of young children with global developmental delay. J Pediatr 2000; 136:593.</a></li><li><a class="nounderline abstract_t">Essex C, Roper H. Lesson of the week: late diagnosis of Duchenne's muscular dystrophy presenting as global developmental delay. BMJ 2001; 323:37.</a></li><li><a class="nounderline abstract_t">Ciafaloni E, Fox DJ, Pandya S, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr 2009; 155:380.</a></li><li><a class="nounderline abstract_t">Firth HV, Richards SM, Bevan AP, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am J Hum Genet 2009; 84:524.</a></li><li><a class="nounderline abstract_t">Sagoo GS, Butterworth AS, Sanderson S, et al. Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med 2009; 11:139.</a></li><li><a class="nounderline abstract_t">Moeschler JB. Medical genetics diagnostic evaluation of the child with global developmental delay or intellectual disability. Curr Opin Neurol 2008; 21:117.</a></li><li><a class="nounderline abstract_t">Oostlander AE, Meijer GA, Ylstra B. Microarray-based comparative genomic hybridization and its applications in human genetics. Clin Genet 2004; 66:488.</a></li><li><a class="nounderline abstract_t">Ropers HH. Genetics of intellectual disability. Curr Opin Genet Dev 2008; 18:241.</a></li><li><a class="nounderline abstract_t">Hochstenbach R, van Binsbergen E, Engelen J, et al. Array analysis and karyotyping: workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands. Eur J Med Genet 2009; 52:161.</a></li><li><a class="nounderline abstract_t">Boone PM, Bacino CA, Shaw CA, et al. Detection of clinically relevant exonic copy-number changes by array CGH. Hum Mutat 2010; 31:1326.</a></li><li><a class="nounderline abstract_t">Wiszniewski W, Hunter JV, Hanchard NA, et al. TM4SF20 ancestral deletion and susceptibility to a pediatric disorder of early language delay and cerebral white matter hyperintensities. Am J Hum Genet 2013; 93:197.</a></li><li><a class="nounderline abstract_t">Conlin LK, Thiel BD, Bonnemann CG, et al. Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis. Hum Mol Genet 2010; 19:1263.</a></li><li><a class="nounderline abstract_t">Wiszniewska J, Bi W, Shaw C, et al. Combined array CGH plus SNP genome analyses in a single assay for optimized clinical testing. Eur J Hum Genet 2014; 22:79.</a></li><li><a class="nounderline abstract_t">Paciorkowski AR, Fang M. Chromosomal microarray interpretation: what is a child neurologist to do? Pediatr Neurol 2009; 41:391.</a></li><li><a class="nounderline abstract_t">Hersh JH, Saul RA, Committee on Genetics. Health supervision for children with fragile X syndrome. Pediatrics 2011; 127:994.</a></li><li><a class="nounderline abstract_t">Hall SS, Lightbody AA, Reiss AL. Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. Am J Ment Retard 2008; 113:44.</a></li><li><a class="nounderline abstract_t">Smith HS, Swint JM, Lalani SR, et al. Clinical Application of Genome and Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping Review of the Literature. Genet Med 2019; 21:3.</a></li><li class="breakAll">American College of Medical Genetics and Genomics (ACMG) Policy Statement: Points to Consider in the Clinical Application of Genomic Sequencing. Available at: https://www.acmg.net/StaticContent/PPG/Clinical_Application_of_Genomic_Sequencing.pdf (Accessed on May 03, 2016).</li><li><a class="nounderline abstract_t">Johansen Taber KA, Dickinson BD, Wilson M. The promise and challenges of next-generation genome sequencing for clinical care. JAMA Intern Med 2014; 174:275.</a></li><li><a class="nounderline abstract_t">De Vries BB, Winter R, Schinzel A, van Ravenswaaij-Arts C. Telomeres: a diagnosis at the end of the chromosomes. J Med Genet 2003; 40:385.</a></li><li><a class="nounderline abstract_t">Lewendon G, Kinra S, Nelder R, Cronin T. Should children with developmental and behavioural problems be routinely screened for lead? Arch Dis Child 2001; 85:286.</a></li><li class="breakAll">CDC response to Advisory Committee on Childhood Lead Poisoning Prevention Recommendations in "Low Level Lead Exposure Harms Children:  A Renewed Call of Primary Prevention" http://www.cdc.gov/nceh/lead/ACCLPP/activities.htm (Accessed on April 29, 2020).</li><li><a class="nounderline abstract_t">Bouhadiba Z, Dacher J, Monroc M, et al. [MRI of the brain in the evaluation of children with developmental delay]. J Radiol 2000; 81:870.</a></li><li><a class="nounderline abstract_t">Decobert F, Grabar S, Merzoug V, et al. Unexplained mental retardation: is brain MRI useful? Pediatr Radiol 2005; 35:587.</a></li></ol></div><div id="topicVersionRevision">Topic 6189 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, Arlington 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157020" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comprehensive evaluation of the child with intellectual disability or global developmental delays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10624083" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10596263" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Summary of the Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Mental Retardation and Comorbid Mental Disorders. American Academy of Child and Adolescent Psychiatry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10596263" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Summary of the Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Mental Retardation and Comorbid Mental Disorders. American Academy of Child and Adolescent Psychiatry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805709" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : De novo mutations in human genetic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21236634" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of intellectual disability: a meta-analysis of population-based studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740881" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical genetic evaluation of the child with mental retardation or developmental delays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12578916" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22877930" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gender and geographic differences in the prevalence of intellectual disability in children: analysis of data from the national disability registry of Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21124998" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The genetic basis of non-syndromic intellectual disability: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27127621" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Advances in understanding - genetic basis of intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389284" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The epidemiology of mental retardation of unknown cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11806749" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early risk factors for mental retardation: role of maternal age and maternal education.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563898" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Poverty and people with intellectual disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21479223" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Autism and intellectual disability are differentially related to sociodemographic background at birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23020937" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342255" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Genetic evaluation of intellectual disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23895455" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Making headway with genetic diagnostics of intellectual disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12216056" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The epidemiology of mental retardation: challenges and opportunities in the new millennium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941363" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Etiology of mental retardation in children referred to a tertiary care center: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25533962" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Large-scale discovery of novel genetic causes of developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466091" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18570304" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Yield of additional metabolic studies in neurodevelopmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518794" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16721406" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genetics and pathophysiology of mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106270" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Genetics of mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16917849" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20437059" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Copy number variants at Williams-Beuren syndrome 7q11.23 region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18231123" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Smith-Magenis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20803659" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prader-Willi syndrome and Angelman syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23033978" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnostic exome sequencing in persons with severe intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26503795" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Genetic studies in intellectual disability and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24088041" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical whole-exome sequencing for the diagnosis of mendelian disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25326635" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Molecular findings among patients referred for clinical whole-exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26845106" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26809768" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A Diagnosis to Consider in Intellectual Disability: Mowat-Wilson Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28135719" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevalence and architecture of de novo mutations in developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15523501" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28097321" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families With Neurodevelopmental Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27870114" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The Molecular Genetics of Autosomal Recessive Nonsyndromic Intellectual Disability: a Mutational Continuum and Future Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26805781" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20822471" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Genetics of early onset cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20822471" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Genetics of early onset cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22482801" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Fragile X and X-linked intellectual disability: four decades of discovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21956720" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18985075" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21326285" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : De novo MECP2 duplication in two females with random X-inactivation and moderate mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458799" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : MECP2 duplication: possible cause of severe phenotype in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36434914" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : DDX3X Syndrome: Summary of Findings and Recommendations for Evaluation and Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26235985" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644449" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Phenotype and genotype in 101 males with X-linked creatine transporter deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20014364" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : X-linked intellectual disability: unique vulnerability of the male genome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24519770" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The spectrum of PLP1 gene mutations in patients with the classical form of the Pelizaeus-Merzbacher disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23245814" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mutations in the PLP1 gene residue p. Gly198 as the molecular basis of Pelizeaus-Merzbacher phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818730" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Molecular genetics of mitochondrial disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27110944" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prenatal, Perinatal and Neonatal Risk Factors for Intellectual Disability: A Systemic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25497122" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neurodevelopmental outcome after extreme prematurity: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861488" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Investigation of global developmental delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802489" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Etiologic yield of subspecialists' evaluation of young children with global developmental delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11440945" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Lesson of the week: late diagnosis of Duchenne's muscular dystrophy presenting as global developmental delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394035" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344873" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19367186" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317267" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Medical genetics diagnostic evaluation of the child with global developmental delay or intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521975" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Microarray-based comparative genomic hybridization and its applications in human genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18694825" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Genetics of intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19362174" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Array analysis and karyotyping: workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20848651" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Detection of clinically relevant exonic copy-number changes by array CGH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23810381" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : TM4SF20 ancestral deletion and susceptibility to a pediatric disorder of early language delay and cerebral white matter hyperintensities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20053666" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23695279" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Combined array CGH plus SNP genome analyses in a single assay for optimized clinical testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19931159" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Chromosomal microarray interpretation: what is a child neurologist to do?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518720" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Health supervision for children with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173299" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29760485" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical Application of Genome and Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29760485" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinical Application of Genome and Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24217348" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The promise and challenges of next-generation genome sequencing for clinical care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807958" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Telomeres: a diagnosis at the end of the chromosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567935" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Should children with developmental and behavioural problems be routinely screened for lead?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567935" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Should children with developmental and behavioural problems be routinely screened for lead?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10916004" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : [MRI of the brain in the evaluation of children with developmental delay].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15739114" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Unexplained mental retardation: is brain MRI useful?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
